Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4611-4620 Newer>

The Motley Fool February 28, 2008 Brian Lawler	Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful.
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
The Motley Fool February 28, 2008 Brian Lawler	Medicare, Health Care, and Megabucks A new government report forecasts big growth in health-care spending in the next ten years, meaning there will be some major growth opportunities in the pharmaceutical sector.
The Motley Fool February 28, 2008 Brian Lawler	Third Wave Making Tiny Ripples Small molecular-diagnostics developer Third Wave Technologies could be poised for big returns.
The Motley Fool February 28, 2008 Brian Orelli	Mylan Almost Triples Revenue -- Big Deal Mylan's growth seems impressive last year, but that growth was all extrinsic, and it came at a cost.
The Motley Fool February 28, 2008 Brian Lawler	FDA's Mixed Signals for Theravance The FDA gives Theravance frustrating double messages about a lead drug.
The Motley Fool February 27, 2008 Brian Orelli	Everyone's Picking on Anemia Drugs A new study in The Journal of the American Medical Association is adding fuel to the fire about Amgen's and Johnson & Johnson's anemia drugs. Should investors worry?
The Motley Fool February 26, 2008 Brian Orelli	Quick Take: Boston Scientific Gets Approved -- Thrice The medical device maker is granted three FDA approvals in one day.
The Motley Fool February 26, 2008 Brian Orelli	The Less-Flashy Prostate Cancer Treatment GTx shows off clinical trial data for a drug that counters the side effects of prostate cancer treatments.
The Motley Fool February 25, 2008 Brian Orelli	The Biologic That Keeps on Giving Just a month after Abbott Laboratories receives a fifth approval for its anti-inflammatory Humira, the FDA approved the biotech drug to treat yet another disease.
<Older 4611-4620 Newer> Return to current articles.